289 related articles for article (PubMed ID: 24068939)
1. Inactivation of intergenic enhancers by EBNA3A initiates and maintains polycomb signatures across a chromatin domain encoding CXCL10 and CXCL9.
Harth-Hertle ML; Scholz BA; Erhard F; Glaser LV; Dölken L; Zimmer R; Kempkes B
PLoS Pathog; 2013 Sep; 9(9):e1003638. PubMed ID: 24068939
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.
Schmidt SC; Jiang S; Zhou H; Willox B; Holthaus AM; Kharchenko PV; Johannsen EC; Kieff E; Zhao B
Proc Natl Acad Sci U S A; 2015 Jan; 112(2):554-9. PubMed ID: 25540416
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr Virus (EBV) Latent Protein EBNA3A Directly Targets and Silences the
Bazot Q; Paschos K; Allday MJ
J Virol; 2018 Apr; 92(7):. PubMed ID: 29367247
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
Wang A; Welch R; Zhao B; Ta T; Keleş S; Johannsen E
J Virol; 2015 Dec; 90(6):2906-19. PubMed ID: 26719268
[TBL] [Abstract][Full Text] [Related]
5. Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming.
McClellan MJ; Wood CD; Ojeniyi O; Cooper TJ; Kanhere A; Arvey A; Webb HM; Palermo RD; Harth-Hertle ML; Kempkes B; Jenner RG; West MJ
PLoS Pathog; 2013 Sep; 9(9):e1003636. PubMed ID: 24068937
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
Zhao B; Zou J; Wang H; Johannsen E; Peng CW; Quackenbush J; Mar JC; Morton CC; Freedman ML; Blacklow SC; Aster JC; Bernstein BE; Kieff E
Proc Natl Acad Sci U S A; 2011 Sep; 108(36):14902-7. PubMed ID: 21746931
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP.
Skalska L; White RE; Franz M; Ruhmann M; Allday MJ
PLoS Pathog; 2010 Jun; 6(6):e1000951. PubMed ID: 20548956
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of
Gillman ACT; Parker G; Allday MJ; Bazot Q
J Virol; 2018 Nov; 92(21):. PubMed ID: 30135119
[TBL] [Abstract][Full Text] [Related]
9. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.
Su C; Lu F; Soldan SS; Lamontagne RJ; Tang HY; Napoletani G; Farrell PJ; Tempera I; Kossenkov AV; Lieberman PM
PLoS Pathog; 2021 Aug; 17(8):e1009834. PubMed ID: 34352044
[TBL] [Abstract][Full Text] [Related]
10. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
J Virol; 2020 May; 94(10):. PubMed ID: 32132242
[TBL] [Abstract][Full Text] [Related]
11. EBNA3C Directs Recruitment of RBPJ (CBF1) to Chromatin during the Process of Gene Repression in EBV Infected B Cells.
Kalchschmidt JS; Gillman AC; Paschos K; Bazot Q; Kempkes B; Allday MJ
PLoS Pathog; 2016 Jan; 12(1):e1005383. PubMed ID: 26751214
[TBL] [Abstract][Full Text] [Related]
12. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
Wood CD; Carvell T; Gunnell A; Ojeniyi OO; Osborne C; West MJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021904
[TBL] [Abstract][Full Text] [Related]
13. EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes in B cells.
Glaser LV; Rieger S; Thumann S; Beer S; Kuklik-Roos C; Martin DE; Maier KC; Harth-Hertle ML; Grüning B; Backofen R; Krebs S; Blum H; Zimmer R; Erhard F; Kempkes B
PLoS Pathog; 2017 Oct; 13(10):e1006664. PubMed ID: 28968461
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
Pegman PM; Smith SM; D'Souza BN; Loughran ST; Maier S; Kempkes B; Cahill PA; Simmons MJ; Gélinas C; Walls D
J Virol; 2006 Aug; 80(16):8133-44. PubMed ID: 16873269
[TBL] [Abstract][Full Text] [Related]
15. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.
Portal D; Zhao B; Calderwood MA; Sommermann T; Johannsen E; Kieff E
Proc Natl Acad Sci U S A; 2011 May; 108(19):7808-13. PubMed ID: 21518914
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does not require RBP-Jkappa.
Bourillot PY; Waltzer L; Sergeant A; Manet E
J Gen Virol; 1998 Feb; 79 ( Pt 2)():363-70. PubMed ID: 9472621
[TBL] [Abstract][Full Text] [Related]
17. EBV epigenetically suppresses the B cell-to-plasma cell differentiation pathway while establishing long-term latency.
Styles CT; Bazot Q; Parker GA; White RE; Paschos K; Allday MJ
PLoS Biol; 2017 Aug; 15(8):e2001992. PubMed ID: 28771465
[TBL] [Abstract][Full Text] [Related]
18. EBNA2 and Its Coactivator EBNA-LP.
Kempkes B; Ling PD
Curr Top Microbiol Immunol; 2015; 391():35-59. PubMed ID: 26428371
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA.
Waltzer L; Perricaudet M; Sergeant A; Manet E
J Virol; 1996 Sep; 70(9):5909-15. PubMed ID: 8709211
[TBL] [Abstract][Full Text] [Related]
20. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
Beer S; Wange LE; Zhang X; Kuklik-Roos C; Enard W; Hammerschmidt W; Scialdone A; Kempkes B
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2200512119. PubMed ID: 35857872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
